ArticleGastroenterology research and practice2019
Oral Phosphatidylcholine Improves Intestinal Barrier Function in Drug-Induced Liver Injury in Rats.
Article in Gastroenterology research and practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Critical Illness-Related Alterations in Plasma Phosphatidylcholine Species Reveal Selective Induction of PC 32:0.International journal of molecular sciences · 2026Article
- Partial body mass regain attenuates lipid utilization and alters the hepatic lipidome linked to HDL dysfunction during metabolic syndrome in male rats.Physiological reports · 2026Article
- Multi-Omics Analysis Uncovers Acute Hypoxia-Induced Gut Damage and the Underlying Protective Mechanisms of Probiotic Clostridium butyricum B3 in Yellow Catfish (Pelteobagrus fulvidraco).Probiotics and antimicrobial proteins · 2026Article
- Assessment of the hepatoprotective effect of a multi-component preparation containing phospholipids, selected amino acids, betaine, and milk thistle extract in dogs with asymptomatic elevation of liver parameters: a pilot study.Frontiers in veterinary science · 2026Article
- Corn Bran IDF and Polyphenol-Reduced IDF Alleviate Low-Dose 3-MCPD-Induced Toxicity by Modulating Gut Microbiota and Intestinal Barrier.Foods (Basel, Switzerland) · 2025Article
- Article
- DLPC induces ferroptosis in cancer cells.Acta biochimica et biophysica Sinica · 2024Article
- Unveiling the "hidden quality" of the walnut pellicle: a precious source of bioactive lipids.Frontiers in plant science · 2024Article
- Design and optimization of cranberry extract loaded bile salt augmented liposomes for targeting of MCP-1/STAT3/VEGF signaling pathway in DMN-intoxicated liver in rats.Drug delivery · 2022Article
- Exploring the Phosphatidylcholine in Inflammatory Bowel Disease: Potential Mechanisms and Therapeutic Interventions.Current pharmaceutical design · 2022Review
- Dietary ε-Polylysine Affects on Gut Microbiota and Plasma Metabolites Profiling in Mice.Frontiers in nutrition · 2022Article
- Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis.Diagnostics (Basel, Switzerland) · 2021Article
- Bioactive Lipids and Their Derivatives in Biomedical Applications.Biomolecules & therapeutics · 2021Review
- Mining Anti-Inflammation Molecules FromFrontiers in cellular and infection microbiology · 2021Article
- Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia.BMJ open gastroenterology · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePhosphatidylcholine (PC) is the major surface-active phospholipid and creates a hydrophobic nature to the surface. It has been reported to reverse the progression of liver fibrosis and to improve liver function. The aim of the present study was to evaluate the effects of orally administered PC on intestinal barrier function (IBF) in rats with drug-induced liver injury.
methodRats with carbon tetrachloride- (CCl4-) induced liver injury were treated with 100 mg/kg PC once daily for 21 days. The effects of PC therapy on (i) liver function and portal pressure, (ii) intestinal and hepatic histology, and (iii) plasma endotoxin, diamine oxidase (DAO), and tumour necrosis factor- (TNF-)
resultsPC therapy reduced portal pressure and improved the liver function in CCl4-induced liver injury. In PC-treated liver injury rats, collagen fibres were gradually decreased, while the disordered arrangement of hepatocytes and disorganized hepatic lobules were partially repaired, and inflammatory cell infiltration was decreased in the fibrous tissue. Lower inflammatory cell infiltration in the ileum improved intestinal histology, and reduced serum DAO levels were observed in PC-treated cirrhotic rats. These changes were associated with reduced inflammatory activity, as indicated by decreased serum TNF-
conclusionsThese results suggest that PC therapy is hepatoprotective and is able to restore IBF and reduce endotoxaemia in rats with drug-induced liver injury.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.